Savara (SVRA)
4.76
+0.13 (2.81%)
Upcoming Events
Latest Headlines
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
October 12, 2026 4:05 PM - BizWire
JPMorgan Starts Savara (SVRA) at Overweight
October 7, 2026 5:15 AM - StreetInsider
Savara (SVRA) Reiterated at Market Outperform by Citizens on Molbreevi Optimism
October 7, 2026 4:35 AM - StreetInsider
Form 4 Savara Inc For: Sep 24 Filed by: Parker Braden C.
September 25, 2026 7:02 PM - SEC Filing
Increasing unusual call option volume: BBD SVRA SGHC ABUS XP U GDDY ACAD AUPH TSSI LTH
September 25, 2026 6:06 AM - StreetInsider
Savara to present IMPALA-2 trial data at ERS Congress in Barcelona
August 24, 2026 4:05 PM - StreetInsider
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European
August 24, 2026 4:05 PM - BizWire
Savara Announces New Employment Inducement Grant
August 20, 2026 4:05 PM - BizWire
Form SCHEDULE 13G/A Savara Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
August 14, 2026 8:23 AM - SEC Filing
Form S-8 Savara Inc
August 11, 2026 5:12 PM - SEC Filing
Form 10-Q Savara Inc For: Jun 30
August 11, 2026 4:06 PM - SEC Filing
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026 4:05 PM - BizWire
Savara wins European and Australian patents for Molbreevi through 2041
July 30, 2026 8:05 AM - StreetInsider
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
July 30, 2026 8:05 AM - BizWire
Form 4 Savara Inc For: Jul 15 Filed by: Lutz Robert Matthew
July 24, 2026 6:25 PM - SEC Filing
Full Article List
